Abstract
Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents
Volume: 10 Issue: 3
Author(s): Yolanda Diebold, Laura Contreras-Ruiz, Isabel Arranz-Valsero and Laura Garcia-Posadas
Affiliation:
Keywords: Anti-inflammatory drugs, corticosteroids, drug delivery, eye disease, nanomedicine, nanoparticles, NSAIDs, ocular drug administration, Ophthalmology, OCULAR ANTI-INFLAMMATORY THERAPY
Abstract: Anti-inflammatory agents are routinely used to treat inflammatory diseases affecting both anterior and/or posterior segments of the eye. Corticosteroids and NSAIDs can be administered either topically onto the ocular surface structures or injected into the eye. However, one of the most important handicaps of ocular treatments is the presence of several anatomical and physiological barriers in the eye that drastically reduce drug access to the target site. The hydrophobicity of anti-inflammatory agents, low drug bioavailability, and the invasiveness of intraocular drug delivery are main reasons to explore the potential application of drug delivery-related technologies to develop new antiinflammatory ocular therapies. This review summarizes conventional anti-inflammatory treatments for ocular diseases and the ongoing research efforts to develop improved drug delivery systems. Micro-size intraocular implants, microparticles, nanoparticles, and liposomes are the preferred delivery systems in study.
Export Options
About this article
Cite this article as:
Diebold Yolanda, Contreras-Ruiz Laura, Arranz-Valsero Isabel and Garcia-Posadas Laura, Drug Delivery Systems for Ophthalmic Administration of Antiinflammatory Agents, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (3) . https://dx.doi.org/10.2174/1871523011109030203
DOI https://dx.doi.org/10.2174/1871523011109030203 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuropharmacological Aspects of Crocus sativus L.: A Review of Preclinical Studies and Ongoing Clinical Research
CNS & Neurological Disorders - Drug Targets Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Prospectives for Gene Therapy of Retinal Degenerations
Current Genomics Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Coagulation Factor XIIIA (F13A1): Novel Perspectives in Treatment and Pharmacogenetics
Current Pharmaceutical Design Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design Polymeric Nanoparticles for Ophthalmic Drug Delivery: An Update on Research and Patenting Activity
Recent Patents on Nanomedicine Current Antioxidant Molecular Therapies for Oxidative Stress-Related Ailments
Current Gene Therapy Microcirculation of the Diabetic Foot
Current Pharmaceutical Design A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Diabetic Retinopathy and Atherosclerosis: is there a Link?
Current Diabetes Reviews Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Management of Idiopathic Intracranial Hypertension During the COVID-19 Pandemic
Reviews on Recent Clinical Trials Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design The Hellp Syndrome: A Review
Current Women`s Health Reviews Diffusion of Macromolecule Through Retina After Experimental Branch Retinal Vein Occlusion and Estimate of Intraretinal Barrier
Current Drug Metabolism Controversies in NSAIDs Use in Cataract Surgery
Current Pharmaceutical Design